Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/9948
Title: HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey
Authors: Sayan, M.
Sargin, F.
Inan, D.
Sevgi, D.Y.
Celikbas, A.K.
Yasar, K.
Kaptan, F.
Keywords: antivirus agent
nonnucleoside reverse transcriptase inhibitor
RNA directed DNA polymerase inhibitor
thymidine derivative
anti human immunodeficiency virus agent
Human immunodeficiency virus proteinase
Human immunodeficiency virus proteinase inhibitor
RNA directed DNA polymerase
virus RNA
antiviral resistance
Article
child
cohort analysis
female
human
Human immunodeficiency virus 1
Human immunodeficiency virus 1 infection
Human immunodeficiency virus infected patient
major clinical study
male
preschool child
prevalence
priority journal
Turkey (republic)
virus mutation
virus transmission
world health organization
adult
CD4 lymphocyte count
drug effects
gene expression
genetics
growth, development and aging
Human immunodeficiency virus infection
metabolism
mutation
transmission
Adult
Anti-HIV Agents
CD4 Lymphocyte Count
Drug Resistance, Viral
Female
Gene Expression
HIV Infections
HIV Protease
HIV Protease Inhibitors
HIV Reverse Transcriptase
HIV-1
Humans
Male
Mutation
Prevalence
Reverse Transcriptase Inhibitors
RNA, Viral
Turkey
Publisher: Mary Ann Liebert Inc.
Abstract: HIV-1 replication is rapid and highly error-prone. Transmission of a drug-resistant HIV-1 strain is possible and occurs within the HIV-1-infected population. In this study, we aimed to determine the prevalence of transmitted drug resistance mutations (TDRMs) in 1,306 newly diagnosed untreated HIV-1-infected patients from 21 cities across six regions of Turkey between 2010 and 2015. TDRMs were identified according to the criteria provided by the World Health Organization's 2009 list of surveillance drug resistance mutations. The HIV-1 TDRM prevalence was 10.1% (133/1,306) in Turkey. Primary drug resistance mutations (K65R, M184V) and thymidine analogue-associated mutations (TAMs) were evaluated together as nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations. NRTI TDRMs were found in 8.1% (107/1,306) of patients. However, TAMs were divided into three categories and M41L, L210W, and T215Y mutations were found for TAM1 in 97 (7.4%) patients, D67N, K70R, K219E/Q/N/R, T215F, and T215C/D/S mutations were detected for TAM2 in 52 (3.9%) patients, and M41L + K219N and M41L + T215C/D/S mutations were detected for the TAM1 + TAM2 profile in 22 (1.7%) patients, respectively. Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, and L90M). In conclusion, long-term and large-scale monitoring of regional levels of HIV-1 TDRMs informs treatment guidelines and provides feedback on the success of HIV-1 prevention and treatment efforts. © Copyright 2016, Mary Ann Liebert, Inc. 2016.
URI: https://hdl.handle.net/11499/9948
https://doi.org/10.1089/aid.2015.0110
ISSN: 0889-2229
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
selda sayın kutlu.pdf149.1 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

20
checked on Nov 30, 2024

WEB OF SCIENCETM
Citations

19
checked on Dec 4, 2024

Page view(s)

32
checked on Aug 24, 2024

Download(s)

22
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.